• Source : Press Release
  • Date : 2022-04-18
  • Event type : Phase 2
  • Companies : Roche, IPHARMA, LLC

IPHARMA Received Permission to Conduct Phase II-III Clinical Trials

IPHARMA received permission from the Ministry of Health to conduct a phase II-III clinical trial of the drug VM-1500A-LAI (OOO Viriom).

Protocol No. IV-VM1500ALAI-03 " A multicenter, open, randomized, active-controlled study to evaluate the efficacy and safety of switching to the VM1500A-LAI + 2 NRTI regimen from standard 1st line therapy in HIV-1-infected patients ."

The study will take place in 10 cities with the participation of 505 patients.